论文部分内容阅读
铂类抗肿瘤药物因其独特的抗肿瘤机制、广泛的抗肿瘤谱、良好的抗肿瘤效果成为目前临床治疗恶性肿瘤最为有效的药物之一.但目前上市的铂类抗肿瘤药物都属于经典的顺铂类药物,由于其结构的相似性,使得其在临床应用中不可避免地出现了顺式铂类药物的毒副作用和耐药性等问题.双核铂类药物是一类新型的非经典铂类抗肿瘤药物,它的设计突破了经典顺铂类药物的构效关系,其作用机制不同于经典铂类药物,不易产生耐药性,因此受到广泛的关注.本文以桥连基团的不同将其归纳分类,主要有三大类:以多胺为桥连基团的双核铂配合物,以氨基酸或二羧酸为桥连基团的双核铂配合物,以卤素离子为桥连基团的双核铂配合物.
Because of its unique anti-tumor mechanism, broad anti-tumor spectrum and good anti-tumor effect, platinum anti-tumor drugs become one of the most effective drugs in the clinical treatment of malignant tumors at present.However, the currently available anti-tumor drugs of platinum are all classical Cisplatin drugs, due to their structural similarities, make their clinical application inevitable problems such as side effects and drug resistance of cisplatin drugs, etc. Binuclear platinum drugs are a new class of non-classical platinum The design of anticancer drugs, whose design has broken through the structure-activity relationship of classical cisplatin drugs, has a wide range of concerns due to its mechanism of action is different from that of classical platinum drugs and is not easy to produce drug resistance.In this paper, There are three main categories: dinuclear platinum complexes with polyamine bridging groups, dinuclear platinum complexes with amino acids or dicarboxylic acids as bridging groups, halogenated bridging groups Dinuclear platinum complexes.